FIELD: medicine.
SUBSTANCE: invention represents antibodies having an anti-MN-protein specific antigen linkage site, combinations and methods of application of such antibodies.
EFFECT: invention can be effectively used in treating and diagnosing MN-related disorders.
13 cl, 49 dwg, 4 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF CTLA-4 ANTIBODIES | 2005 |
|
RU2346702C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2014 |
|
RU2678138C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2013 |
|
RU2639522C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2011 |
|
RU2598258C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND/OR PREVENTION | 2013 |
|
RU2632645C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND PREVENTION | 2012 |
|
RU2641260C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2011 |
|
RU2607366C2 |
| ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF | 2010 |
|
RU2575612C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 2011 |
|
RU2567657C2 |
